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Abstract 
Background Around 10% of all thrombotic cerebrovascular events (CVE) occur in young 
population and in a large proportion of those the trigger remains undetermined. Antiphospholipid 
antibodies (aPL) are recognised risk factors for ischaemic stroke and recurrent thrombotic events; 
however, the frequency of aPL in young people with CVE is still an unresolved issue. 
Objectives To estimate the frequency of aPL in young adults with CVE and to determine whether 
aPL-positive young individuals are at greater risk of CVE when compared with individuals without 
aPL by systematically reviewing the literature. 
Methods Medline reports published between 1970 and 2013 investigating the presence of aPL in 
young patients (<50 years old) with CVE were included. The median frequency for positive aPL, 
including lupus anticoagulant, anticardiolipin antibodies (aCL) and antibodies against 
β2Glycoprotein I (anti-β2GPI), was calculated for stroke and transient ischaemic attacks. 
Findings This systematic review is based on available data from 5217 patients and controls from 43 
studies analysing the frequency of aPL in young patients with CVE. The overall aPL frequency was 
estimated as 17.4% (range 5%–56%) for any CVE, 17.2% (range 2%–56%) for stroke and 11.7% 
(range 2%–45%) for transient ischaemic attack (TIA). The presence of aPL increased the risk for 
CVE by 5.48-fold (95% CI 4.42 to 6.79). Based on available data, the frequency of aPL in young 
patients with CVE can be estimated at 17%, rising up to 22% for aCL in patients with stroke. The 
presence of aPL seems to confer a fivefold higher risk for stroke or TIA when compared with 
controls. However, variability in test reproducibility and cut-off definition still represent an 
important methodological limitation for the current diagnostic testing for aPL. These observations 
should be confirmed by appropriately designed population studies. 
Introduction 
Around 10% of all thrombotic cerebrovascular events (CVE) occur in young population defined as 
younger than 50 years old;1 in the majority of these patients, the cause of the ischaemic stroke 
remains undetermined.2 
Arterial thrombosis is a major clinical manifestation of the antiphospholipid syndrome (APS), an 
autoimmune condition characterised by thrombotic events and/or pregnancy morbidity with 
persistently positive antiphospholipid antibodies (aPL).3 Considering all patients with cerebral 
ischaemia, the prevalence of aPL seems rather high in young adults,4 who might constitute a 
subgroup at high risk for recurrence. 
Very recently, through the support of the Antiphospholipid Syndrome Alliance for Clinical Trials 
and International Networking (APS ACTION), a systematic review aiming to estimate the 
frequency of clinically significant aPL profiles in the general population (no age limit) was 
completed. This study revealed that aPL (by any criteria test) are seen in approximately 14% of 
individuals with stroke.5 
In patients with CVE aged <50, however, the prevalence of aPL and the risk for CVE associated 
with these aPL are still being inconsistently reported. Therefore, the primary objective of this study 
was to estimate the frequency of aPL in young adults (<50 years old) with CVE. The second goal 
was to determine whether aPL-positive young individuals have a greater risk of an episode of 
ischaemic stroke when compared with individuals without aPL. 
METHODS  
Literature search  
A detailed literature search strategy has been developed a priori. Key words and subject terms used 
in the search included: ‘stroke’ [MeSH Terms] OR stroke [Text Word], ‘(‘arteries’ [MeSH Terms] 
OR ‘arteries’ [All Fields] OR ‘arterial’ [All Fields]) AND (‘thrombosis’ [MeSH Terms] OR 
‘thrombosis’[All Fields]);’ ‘antibodies, anticardiolipin’ [MeSH Terms] OR (‘antibodies’ [All 
Fields] AND ‘anticardiolipin’ [All Fields]) OR ‘anticardiolipin antibodies’ [All Fields] OR 
(‘anticardiolipin’ [All Fields] AND ‘antibodies’ [All Fields]);’ and ‘antibodies, antiphospholipid’ 
[MeSH Terms] OR (‘antibodies’ [All Fields] AND ‘antiphospholipid’ [All Fields]) OR 
‘antiphospholipid antibodies’ [All Fields] OR (‘antiphospholipid’ [All Fields] AND ‘antibodies’ 
[All Fields])’, ‘lupus coagulation inhibitor’ [MeSH Terms] OR (‘lupus’ [All Fields] AND 
‘coagulation’ [All Fields] AND ‘inhibitor’ [All Fields]) OR ‘lupus coagulation inhibitor’ [All 
Fields] OR (‘lupus’ [All Fields] AND ‘anticoagulant’ [All Fields]) OR ‘lupus anticoagulant’ [All 
Fields]’, anti-beta [All Fields] AND 2 [All Fields] 
The search strategy was applied to Ovid MEDLINE (R) In-Process & Other Non-Indexed Citations 
and Ovid MEDLINE (R) 1946 to present. The grey literature was searched by applying a similar 
strategy to Google Scholar, PubMed and the Proquest Dissertation and Theses databases. 
Additional references were identified from manual review of the reference lists of included articles.  
Study selection 
Potential studies identified with the above search strategy were exported to an electronic reference 
management software program (RefWorks V.2.0). Duplicate studies were identified and removed 
using the filter functions ‘exact duplicates’ and ‘close duplicates. Two independent reviewers (SS 
and MLB) reviewed all potential studies. Eligibility was first determined by review of the title and 
abstract and then by full article review. Disagreements were resolved by consensus; if consensus 
was not achieved, a third party (GS or MK) provided an assessment of eligibility. As the data on 
eligibility were dichotomous (eligible: yes/no), inter-rater agreement at both the title and abstract 
review and the full article review stages were determined by calculation of Cohen's κ coefficient.6 
Inclusion and exclusion criteria 
A study was included if (1) it reported on the laboratory investigation of any aPL and confirmed 
CVE (2) included patients aged <50 years. A study was excluded if no information about the age of 
included patients was given. Review articles, case report and case series with a sample size of five 
or fewer were excluded from the analysis. 
Risk of bias assessment 
Two reviewers independently assessed the risk of bias of individual studies using the Newcastle–
Ottawa Scale (NOS) for cohort studies, and the NOS for case control studies when appropriate. The 
NOS is a scoring tool used to assess quality of evidence and risk of bias for non-randomised studies 
included in meta-analyses. This tool is chosen as its face and content validity as well as its inter-
rater reliability has been well established.7 
The criterion validity and intra-rater reliability of this tool were actively determined. The overall 
quality of evidence was determined using GRADE criterion and summarised using GRADE 
profiler. 
Risk of publication bias assessment 
To assess publication bias, a visual review of the symmetry of the funnel plot was performed. The 
limitations of using the funnel plot for the assessment of publication bias (particularly in a topic 
area with relatively few, relatively small publications) were also considered. 
Data extraction 
All the papers were scrutinised for the following: (1) study design (retrospective, prospective, case-
control, cross-sectional and case series); (2) number of patients, sex and age (mean, range); (3) type 
of outcome; (4) number and type of aPL tests used (criteria tests vs non-criteria);8 (5) definition of 
‘positive criteria aPL’ (low, medium or high titre, or other) as per the study's definition; (6) 
confirmation of criteria aPL, at least 6 weeks9 or 12 weeks8 apart; and (7) frequency of positive aPL 
in the study population (defined by sex and age range). 
Data were explored to determine if sources of heterogeneity could be explained by the following a 
priori hypotheses: study design (cohort vs case-control); reported medical comorbidities in the 
patient population; and the aPL type and methods used for laboratory aPL testing (including the 
number of aPL tests performed). Indeed, we can hypothesise that each of these subgroup analyses 
could account for potential heterogeneity in the pooled estimate. 
Statistical analysis 
Inter-rater agreement was determined using a Cohen's κ online calculator. A κ value between 0.40 
and 0.59 will be considered fair agreement; 0.60 and 0.74 will be considered good agreement; and 
≥0.75 will be considered excellent agreement. Software such as Review Manager can be used for 
generating forest plots and the funnel plot. 
Given the non-parametric distribution of our data, we expressed aPL frequency as median (range). 
First, we calculated the frequency of aPL positivity of any aPL test. When possible, the frequency 
was estimated for each of the aPL criteria test (anticardiolipin antibodies (aCL), anti-β2GPI and 
lupus anticoagulant (LA)) and non-criteria aPL tests (antibodies against prothrombin, 
phosphatydilserine, phosphatidylinositol, phosphatydilethanolamine). We then estimated the overall 
frequency of the three aPL criteria tests separately for studies confirming aPL positivity between 6 
and 12 weeks apart versus studies completed without aPL confirmation. Prospective versus non-
prospective studies (case series, retrospective, case-control and cross-sectional) were also analysed. 
When reported, ORs with 95% CI (OR (95% CI)) for CVE were recorded. When not available, they 
were calculated, if possible, by means of contingency tables. In case-control and cross-sectional 
studies, contingency tables were used to compare the proportion of aPL in patients with and without 
CVE. In prospective studies, contingency tables were established as previously reported.10 ,11  
Briefly, when CVE was the enrolment criterion, the OR (95% CI) was calculated by comparing the 
proportion of aPL in patients with or without recurrent CVE during follow-up. When positivity for 
aPL was the enrolment criterion, the OR (95% CI) was calculated by comparing the rates of CVE 
during follow-up of patients grouped, if possible, according to different antibody type and titres. 
Results 
A total of 840 citations were identified through the literature search from January 1970 to 
September 2013. A schematic representation of the results of the search strategy is given in figure 1. 
A total of 43 articles assessing the frequency of aPL in patients aged <50 years with CVE (stroke 
and/or transient ischaemic attack (TIA)) were retrieved.4 ,12–54 As per inclusion criteria, all the 
studies enrolled patients aged <50 years, with a median age of 37 (range 16–50). Overall, all studies 
included gave information on 3349 patients and 1868 controls. While most of the studies were of a 
retrospective design, six prospective studies contributed with 408 patients.4 ,1,2–
16 Table 1 summarises the characteristics of the included studies. Subgroup analysis aiming at 
estimating whether aPL-positive young individuals have a greater risk for CVE when compared 
with individuals without aPL was possible in 15 studies.4 ,9 ,12-15 ,17,18 ,22 ,24 ,31 ,33 ,37 ,47 ,54. 
Concomitant thrombotic risk factors for CVE were reported in 88% of the studies. However, the 
role of these risk factors was statistically evaluated in only a minority of the studies and reported by 
very heterogeneous methods, either in terms of the selection of the stated risk factor, their definition 
and the outcome. This approach limited the possibility of further multivariate adjustments when 
analysing the aPL-induced risk. 
All the studies were performed in patients without a concomitant autoimmune disease. However, 
nine cases out of 3349 (0.26%) were diagnosed as having systemic lupus erythematosus after 
further evaluation following or in concomitance with the CVE episode. 
Concomitant thrombotic risk factors for CVE were reported in 88% of the studies. However, the 
role of these risk factors was statistically evaluated in only a minority of the studies and reported by 
very heterogeneous methods, either in terms of the selection of the stated risk factor, their definition 
and the outcome. This approach limited the possibility of further multivariate adjustments when 
analysing the aPL-induced risk. All the studies were performed in patients without a concomitant 
autoimmune disease. However, nine cases out of 3349 (0.26%) were diagnosed as having systemic 
lupus erythematosus after further evaluation following or in concomitance with the CVE episode. 
Estimated frequency of aPL in young patients with CVE 
Table 2 reports the median (range) values for aPL frequency, subgrouped according to the type of 
aPL (aCL, anti-β2GPI, LA and non-criteria aPL). The overall aPL frequency was estimated as 
17.4% (range 5–56) for CVE, 17.2% (range 2–56) for stroke and 11.7% (range 2–45) for TIA. 
When subanalysing studies with and without the aPL positivity confirmation by retesting between 6 
and 12 weeks apart, the overall aPL frequency was 17.2% (range 2–55) and 18.02% (range 3–55), 
respectively (table 3). 
As expected, although not statistically significant, a tendency for lower frequency of aPL was found 
in prospective studies when comparing with non-prospective ones (10.31% (range 3–42) and 
18.92% (range 2–59), respectively). 
Risk estimation for CVE in aPL-positive young individuals 
The OR (95% CI) of aPL for CVE was analysed in 15 studies on 1081 patients and 1868 controls 
(figure 2). Overall, 13 out of 15 studies (86.6%) reported significant associations between aPL and 
CVE, with a cumulative OR of 5.48 (95% CI 4.42 to 6.79). Only two studies failed to confirm the 
association between any aPL and CVE.19 ,29 
 
Discussion 
CVE are one of the leading causes of mortality, with a reported annual 6 million fatal events 
worldwide.1 While stroke mainly affects elderly people, yet approximately 10% occurs in patients 
aged 50 or less.55 Despite these alarming figures, limited data exist on the frequency of other non-
conventional risk factors in young population affected by CVE. 
In this study, we estimate that aPL, by any test included in the classification criteria,8 are positive in 
approximately 17% of patients with CVE under the age of 50. Among these aPL, aCL seems to be 
the more frequently detected, with an estimated frequency of 22% in young patients with stroke. 
This is the first comprehensive systematic analysis of studies investigating the association of aPL 
with CVE in young patients aged <50 years. In contrast to Bushnell and Goldstein,56 we have 
included in the statistical model only those studies that focused solely and exclusively on young 
adults. 
Recently, Andreoli et al,57 in another work on behalf of the APS ACTION, investigated the 
frequency of aPL in the general population with pregnancy morbidity, stroke, myocardial infarction 
and deep venous thrombosis, providing the first attempt to evaluate the prevalence of aPL in 
patients experiencing APS-related clinical manifestations. These authors estimated aPL positivity in 
around 13.5% of individuals with stroke. However, their analysis involved a very wide age 
population ranging from 11 to 92 years old.57 In our study where young adults, a subgroup at high 
risk for recurrence,4 were analysed, we found a higher frequency ranging from 15% for anti-β2GPI 
to 22% for aCL and a strong association between aPL and CVE. 
Overall, our results support the concept that aPL could be considered a leading cause of CVE in 
young adults. However, robust scientific data from large controlled population studies to support 
this statement are still lacking. An important limitation to our analysis is that adequate controls 
groups, crucial for the calculation of risk estimation, were available for only a few studies.4 ,9 ,12–
15 ,17 ,18 ,22 ,24 ,31 ,33 ,37 ,47 ,54 Moreover, among these, the results of studies with less than 30 patients 
produced quantified OR with wide CIs and poor test accuracy as expected.58 Variability in test 
reproducibility and cut-off definition represent an important methodological limitation for the 
current diagnostic testing for aPL (table 1). In our systematic review, we observed that both aCL 
and anti-β2GPI assays were widely heterogeneous with respect to reporting the cut-off for ‘aPL 
positivity.’ Approximately 60% of the papers that related to aCL used a low cut-off value (<20 
units) for the definition of positive results. Such a cut-off does not allow stratifying those medium- 
to high-titre patients who would fulfil laboratory criteria according to the international 
consensus.8 Only about 30% of the cited studies included the confirmation of aPL, a step strongly 
recommended for classification. Moreover, the potential for inter-laboratory variability was not 
addressed.59 On the basis of these methodological issues, the risk assessment post-test probabilities 
calculated in this study should be viewed as rough estimates rather than precise calculations. 
However, current evidence supports the concept that the presence of aPL itself is a risk factor rather 
than a diagnostic marker and the risk of thrombosis progressively increases with the increase in 
number of positive aPL tests, regardless of the titre.60–63 
This new concept, once validated in prospective studies, might enrich the clinical workup in terms 
of risk assessment, patient stratification, prognosis and, hopefully, therapeutic approach. 
We acknowledge that our study has some limitations. First, despite the systematic nature of this 
review, combining heterogeneous studies (ie, those from varying patient populations) leads to 
shortcomings in the interpretation of the results. Including only studies from unselected ischaemic 
stroke patients would have provided conclusions that are, perhaps, more generalisable. However, 
this combination of aPL prevalence studies from both selected and unselected patients provided us 
with larger numbers for meaningfully calculating the estimates, making a stronger case. Second, the 
information that could potentially increase the accuracy of the risk estimation, including 
adjustments for clinical or historical factors, physical examination findings, and other diagnostic 
test results, was rarely reported in the analysed studies, impeding the assessment about a potential 
direct causal relationship between aPL and the clinical outcomes. 
In conclusion, this study estimates that the frequency of aPL in young patients with CVE is 17%, 
increasing up to 22% for aCL in patients with stroke. The presence of any aPL seems to confer a 
fivefold increased risk for stroke or TIA when compared with controls without aPL. Evaluating the 
thrombotic risk by including aPL testing can potentially lead to a substantial change in the 
management and, more critically, in the prognosis of these patients. Undoubtedly, these 
observations should be confirmed with appropriately designed population studies. 
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 Figure 1 
Literature search strategy on the association between antiphospholipid antibodies and cerebrovascular 
events. 
 
 
Figure 2 
Association between antiphospholipid antibodies and cerebrovascular events. 
 
Table 1 
Characteristics of the literature on aPL frequency in young people with CVE 
  
N=43 (patients) % 
Publication year 48.8% between 1984 and 2000 
  Definition of aPL positivity cut-off 10–19 U* 25* (1975) 58.14 
 
20–39 U* 4* (309) 9.30 
 
99th percentile 2 (214) 4.65 
 
Not reported 12 (851) 27.91 
Confirmation of aPL 6–12 weeks apart 
 
15 (732) 34.88 
Design of the study Retrospective cohorts/cross-sectional/case series 25 (2190) 58.14 
 
Case-control studies 12 (751) 27.91 
 
Prospective studies 6 (408) 9.30 
Presence of control group 
 
15 (1081) 34.88 
Evaluation of concomitant cardiovascular risk factors†  
 
38 (2789) 88.30 
Autoimmune disease 
 
4 (9) 9.30 
*17/30 (56.6%) defined as IgG anti-phospholipid units (GPL)/IgM anti-phospholipid units (MPM). 
†At least one of the following: smoking, hyperlipidaemia, hypercholesterolaemia, arterial hypertension or diabetes. 
aPL, antiphospholipid antibodies; CVE, cerebrovascular event; N, Number of studies. 
 
 
Table 2 
The frequency of any aPL, aCL, anti-β2GPI, LA test and non-criteria aPL combined in patients with different CVE 
outcomes 
CVE 
aPL aCL IgG/M anti-β2GPI IgG/M LA Non-criteria aPL* 
N Median* N Median* N Median* N Median* N Median† 
CVE (any) 43 17.4 (2–56) 39 18.2 (3–35) 8 13.7 (5–28) 30 15.4 (0–26) 6 14.9 (7–27) 
Stroke 38 17.2 (2–56) 37 22.0 (3–35) 8 13.7 (5–28) 28 15.8 (0–26) 6 14.9 (7–27) 
TIA 13 11.7 (2–45) 12 12.7 (0–23) 0 – 10 13.42 (7–19) 2 3 (2–4) 
*Median is given as median % (range). 
†Antiprothrombin antibodies N=3; antiphosphatidylethanolamine antibodies N=1; antiphosphatidylinositol antibodies 
N=1; antiphosphatidylserine antibodies N=1; N: number of studies. 
aCL, anticardiolipin antibodies; anti-β2GPI, anti-β2-glycoprotein I antibodies; aPL, antiphospholipid antibodies; CVE, 
cerebrovascular event; LA, lupus anticoagulant; TIA, transient ischaemic attack. 
 
 
Table 3 
The overall frequency of criteria antiphospholipid antibodies (aPL) analysed for aPL confirmation and study design 
Overall criteria aPL frequency 
aPL confirmation 
  Yes No Prospective studies Non-prospective studies 
N Median % (range) N Median % (range) N Median % (range) N Median % (range) 
13 17.2 (2–55) 30 18.02 (3–55) 6 10.31 (3–42) 37 18.92 (2–59) 
N, number of studies. 
 
 
